"Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information o ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical ...

In the case of tarlatamab, the molecule binds to CD3 receptors on T-cells and DLL3 on SCLC cells, and it is the first drug in the anti-DLL3 class to be approved for marketing, as well as the first ...

In the case of tarlatamab, the molecule binds to CD3 receptors on T cells and DLL3 on SCLC cells with the aim of stimulating the immune system to destroy the tumour. It’s a well-established ...

The first poster includes positive Investigational New Drug (IND)-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb for small cell lung cancer patients. The second ...

In certain high grade neuroendocrine carcinomas including small cell lung cancer (SCLC), DLL3 is upregulated and specifically expressed on the cell surface in more than 80% of cases. In contrast ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

Additionally, two-thirds of all SCLC patients are diagnosed at extensive stage3. DLL3 is an antigen overexpressed in many neuroendocrine tumors, such as SCLC, and is often associated with poor ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...

First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell ...